Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003150 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
A Phase 3 study of Lymphoma, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 630
- Enrollment target
- 20
- Study locations
NCT00003150 is a Phase 3 study of Lymphoma that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 630 participants, above the 482-participant average among 299 other Lymphoma trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00003150, a Phase 3 study of Lymphoma, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 630 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if combination chemotherapy is more effective with or without rituximab for non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without rituximab in treating older patients who have non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- DRUG doxorubicin hydrochloride
- DRUG CHOP regimen
Study Locations (20)
California
- Cancer Center and Beckman Research Institute, City of Hope - Duarte
- Veterans Affairs Medical Center - Long Beach - Long Beach
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Veterans Affairs Medical Center - West Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Veterans Affairs Outpatient Clinic - Martinez - Martinez
- CCOP - Bay Area Tumor Institute - Oakland
- Chao Family Comprehensive Cancer Center - Orange
- University of California Davis Medical Center - Sacramento
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- David Grant Medical Center - Travis Air Force Base
Arizona
- CCOP - Greater Phoenix - Phoenix
- Veterans Affairs Medical Center - Phoenix (Hayden) - Phoenix
- Veterans Affairs Medical Center - Tucson - Tucson
- Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Veterans Affairs Medical Center - Little Rock (McClellan) - Little Rock
Colorado
- University of Colorado Cancer Center - Denver
- Veterans Affairs Medical Center - Denver - Denver
Alabama
- MBCCOP - Gulf Coast - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 1997-12 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003150
The ClinicalTrials.gov registry entry for NCT00003150 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 482-participant average among 299 other Lymphoma trials with a reported enrollment target (31% higher). The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which prednisone is the first listed.
NCT00003150 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00003150 about?
NCT00003150 is a clinical study titled "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known i...
What is the current status of trial NCT00003150?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 1997-12. Estimated completion is 2006-09.
What conditions does trial NCT00003150 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00003150?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), rituximab (BIOLOGICAL), doxorubicin hydrochloride (DRUG), CHOP regimen (DRUG).
Who is sponsoring clinical trial NCT00003150?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003150 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.